Dr. Halstrom Sleep Apnea & Snoring Clinics

Why should I trust SomnoMed® with my sleep apnea treatment? "SomnoMed® is the world’s largest supplier of oral sleep apnea devices, operating in 28 countries. Since 2004, we’ve helped patients have a comfortable night’s sleep while effectively treating their sleep apnea.

We’ll make your device to the same medical device quality standards that are used for pacemakers to make sure your device is comfortable for your first night – and every night’s sleep."

Dr. Halstrom has chosen the SomnoMed Avant as a best in class device - the brilliant design simplicity combined with precision digital fabrication provides his patients with a treatment solution optimizing comfort and performance.

Dr. Halstrom Sleep Apnea & Snoring Clinics updated their phone number.

Dr. Halstrom Sleep Apnea & Snoring Clinics updated their address.

Study from July 2021 discusses Sleep Apnea and an association with accelerated vascular aging. Over the many years that we have been treating patients studies continue to underline the importance of seeking out an effective treatment for your sleep apnea.

"Sleep Apnea is Associated With Accelerated Vascular Aging: Results From 2 European Community‐Based Cohort Studies"

Abstract

Background
The mechanisms underlying the association between obstructive sleep apnea (OSA) and cardiovascular disease may include accelerated vascular aging. The aim was to compare the magnitude of vascular aging in patients with high versus low risk of OSA.

Conclusions
These data lend support for accelerated vascular aging in individuals with high risk of OSA. This may, at least in part, underlie the association between OSA and cardiovascular disease.

Methods and Results
In 2 community‐based studies, the PPS3 (Paris Prospective Study 3) and the Maastricht Study, high risk of OSA was determined with the Berlin questionnaire (a screening questionnaire for OSA). We assessed carotid artery properties (carotid intima‐media thickness, Young’s elastic modulus, carotid‐femoral pulse wave velocity, carotid pulse wave velocity, carotid diameter using high precision ultrasound echography), and carotid‐femoral pulse wave velocity (in the Maastricht Study only). Regression coefficients were estimated on pooled data using multivariate linear regression. A total of 8615 participants without prior cardiovascular disease were included (6840 from PPS3, 62% men, mean age 59.5±6.2 years, and 1775 from the Maastricht Study, 51% men, 58.9±8.1 years). Overall, high risk of OSA prevalence was 16.8% (n=1150) in PPS3 and 23.8% (n=423) in the Maastricht Study. A high risk of OSA was associated with greater carotid intima‐media thickness (β=0.21; 0.17–0.26), Young’s elastic modulus (β=0.21; 0.17–0.25), carotid‐femoral pulse wave velocity (β=0.24; 0.14–0.34), carotid pulse wave velocity (β=0.31; 0.26–0.35), and carotid diameter (β=0.43; 0.38–0.48), after adjustment for age, s*x, total cholesterol, smoking, education level, diabetes mellitus, heart rate, and study site. Consistent associations were observed after additional adjustments for mean blood pressure, body mass index, or antihypertensive medications.

Quentin Lisan, Thomas van Sloten, Pierre Boutouyrie, Stéphane Laurent, Nicolas Danchin, Frédérique Thomas, Catherine Guibout, Marie‐Cécile Perier, Pieter Dagnelie, Ronald M. Henry, Miranda T. Schram, Raphaël Heinzer, Pedro Marques‐Vidal, Carla J. van der Kallen, Harry J. Crijns, Marleen van Greevenbroek, Koen Reesink, Sebastian Köhler, Manuel Sastry, Xavier Jouven, … See all authors

Originally published26 Jul 2021https://doi.org/10.1161/JAHA.120.021318Journal of the American Heart Association. 2021;10:e021318

Size and collapsibility of the airway - simple as that. Mandibular repositioning devices look to position the lower jaw slightly forward during sleep to open and bring tone to the airway targeting the sound of snoring and sleep apnea events.

Dr. Halstrom & The Silencer - Successfully Treating Sleep Apnea and Snoring Since 1994 - Dr. Halstrom Dr. Halstrom™ Sleep Apnea and Snoring Clinics along with our network of dedicated dental providers have helped thousands of sleep apnea and snoring patients with effective sleep apnea treatment across North America using The Silencer®, with the patented Halstrom Hinge™. Our patented technology ...

ROAD SAFETY

It is important for all drivers to be aware of the signs and symptoms of obstructive sleep apnea, and to actively pursue testing and treatment.

New study using 'STOP-Bang' protocol finds half of truck drivers could need sleep apnea evaluation.

A 2020 study released by the Virginia Tech Transportation Institute found that nearly half of truck drivers are at risk for obstructive sleep apnea. This table compares drivers tested for OSA using commercial driver medical exam (CDME) data compared to the STOP-Bang (SB) sleep apnea screening assessment on the same pool of drivers. A 2020 study released by the Virginia Tech Transportation Institute found that nearly half of truck drivers are at risk for obstructive sleep apnea. This table compares drivers tested for OSA using commercial driver medical exam (CDME) data compared to the STOP-Bang (SB) sleep apnea screening assessment on the same pool of drivers. Virginia Tech Transportation Institute.

Researchers find nearly 50% of truckers may have sleep apnea when using 'STOP-Bang' screening method.

S*x differences in mandibular repositioning device therapy effectiveness in patients with obstructive sleep apnea syndrome.

Study Published in the Journal Sleep Breath. 2019 Sep;23.

PURPOSE: Mandibular repositioning devices (MRDs) are an effective treatment option for obstructive sleep apnea syndrome (OSAS), particularly in patients who
refuse or cannot tolerate continuous positive airway pressure (CPAP). However, s*x differences in the response to therapy and predictors of response are not clearly defined. This analysis of data from the long-term prospective ORCADES trial compared MRD efficacy in men and women with OSAS.

METHODS: The ORCADES study included patients with newly diagnosed mild-to-moderate or severe OSAS who refused or were non-compliant with CPAP. MRD therapy was titrated over 3-6 months.

RESULTS: Overall treatment success rates were 89% in women and 76% in men for those with severe OSAS (AHI > 30/h) rates were 100% and 68%.

CONCLUSIONS: MRD therapy was effective in women with OSA of any severity, with significantly higher response rates compared with men especially in severe OSAS.

Above text selected from full Abstract:
1. Sleep Breath. 2019 Sep;23(3):837-848. doi: 10.1007/s11325-018-1766-8. Epub 2018
Dec 22.